National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure

Apple, Fred S.; Wu, Alan H.B.; Jaffe, Allan S.; Panteghini, Mauro; Christenson, Robert H.; Cannon, Christopher P.; Francis, Gary L.; Jesse, Robert L.; Morrow, David A.; Newby, Lynette; Storrow, Alan B.; Tang, W.H. Wilson; Pagani, F.; Tate, Jillian R.; Ordóñez-Llanos, Jordi; Mair, Johannes

doi:10.1161/circulationaha.107.185266

Cited by 94 publications

(82 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of serial BNP measurements to monitor the treatment of HF is not well established. Caution should be exercised when interpreting the variation in 50% concentration as related to medical therapy, insofar as there is a consistently high biological variation for both BNP and NT-pro-BNP (2) .…”

Section: Bnp In the Assessment Of Cardiac Functionmentioning

confidence: 99%

B-type natriuretic peptide in the evaluation of cardiac function

Valle¹,

Boas²,

Vidal³

et al. 2013

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

B type natriuretic peptide (BNP) and its precursor, the inactive form of NT-pro-BNP, are currently the most studied laboratory parameters in the heart disease spectrum. The assessment of their blood concentrations provides invaluable information on the likelihood, severity and prognosis of the disease. The present review aims to describe the biological determinants, the factors that influence these peptide concentrations, the suggested cutoff values for the diagnosis of heart failure and the use of this biomarker in the assessment of cardiac function.

show abstract

Section: Bnp In the Assessment Of Cardiac Functionmentioning

confidence: 99%

B-type natriuretic peptide in the evaluation of cardiac function

Valle¹,

Boas²,

Vidal³

et al. 2013

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

show abstract

“…16,18 Although signifi cant progress has occurred in the fi eld of biomarkers, important limitations must be considered. General limitations of biomarker research include threats to validity, including chance, generalizability, bias, reproducibility, overfi tting, confounding, 7,14 analytical issues, 19 concerns regarding processing/storage, and false-positive fi ndings due to multiple hypothesis testing, as well as failure to establish incremental utility beyond existing markers 15 and other clinical tools. 16,18 Common limitations in pulmonary biomarker literature include small studies, the lack of replication cohorts, and the paucity of systemic infl ammation, including CRP, SP-D, fi brinogen, IL-6, IL-8, and TNF-a , was associated to changes in FEV 1 over time.…”

Section: Potential Biomarker Applicationsmentioning

confidence: 99%

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Doyle

Pinto-Plata

Morse

et al. 2012

Chest

View full text Add to dashboard Cite

Recent advances in the fi eld of clinical biomarkers suggest that quantifi cation of serum proteins could play an important role in the diagnosis, classifi cation, prognosis, and treatment response of smoking-related parenchymal lung diseases. COPD and idiopathic pulmonary fi brosis (IPF), two common chronic progressive parenchymal lung diseases, share cigarette smoke exposure as a common dominant risk factor for their development. We have recently shown that COPD and interstitial lung disease may represent distinct outcomes of chronic tobacco use, whereas others have demonstrated that both diseases coexist in some individuals . In this perspective, we examine the potential role of peripheral blood biomarkers in predicting which individuals will develop COPD or IPF, as well as their usefulness in tracking disease progression and exacerbations. Additionally, given the current lack of sensitive and effective metrics to determine an individual's response to treatment, we evaluate the potential role of biomarkers as surrogate markers of clinical outcomes. Finally, we examine the possibility that changes in levels of select protein biomarkers can provide mechanistic insight into the common origins and unique individual susceptibilities that lead to the development of smoking-related parenchymal lung diseases. This discussion is framed by a consideration of the properties of ideal biomarkers for different clinical and research purposes and the best uses for those biomarkers that have already been proposed and investigated.CHEST 2012; 142(4):1027-1034Abbreviations: BODE 5 BMI, airfl ow obstruction, dyspnea, and exercise capacity; CCL-18 5 CC-chemokine ligand-18; CRP 5 C-reactive protein; IPF 5 idiopathic pulmonary fi brosis; KL-6 5 Krebs von den Lungen-6; MMP 5 matrix metalloproteinase; SP 5 surfactant protein; TNF-a 5 tumor necrosis factor-a

show abstract

“…Also in acute myocardial infarction, the intact troponin subunits rapidly disappear from the circulation during the early hours after infarction, while immunoreactive troponin fragments remain [11]. Furthermore it could be noted that for cTnI, for which there are a number of instruments and methods available, including antibodies and calibrators from several manufacturers, the results vary 20-fold to 40-fold in the reported clinical investigations [1,29]. We think that development of new SPR assays may in future studies contribute to the further understanding of these fundamental questions.…”

Section: Interassay Comparison Of Biacore 2000 and Elecsys 2010mentioning

confidence: 99%

“…Three troponin forms are released from heart muscle cells during cardiac injury: troponin T (TnT), troponin I (TnI), and troponin C (TnC) [1]. The release is caused by a combination of a disruption of the cardiomyocyte membrane and a dissociation of the thin-filament troponin complex in the cell [2][3].…”

Section: Introductionmentioning

confidence: 99%

Monitoring of troponin release from cardiomyocytes during exposure to toxic substances using surface plasmon resonance biosensing

2010

View full text Add to dashboard Cite

Troponin T (TnT) is a useful biomarker for studying drug-induced toxicity effects on cardiac cells. In this paper, we describe how a surface plasmon resonance (SPR) biosensor was applied to monitor the release of TnT from active HL-1 cardiomyocytes in vitro when exposed to cardiotoxic substances. Two monoclonal human TnT antibodies were compared in the SPR immunosensor for analysing of the TnT release. The detection limit of TnT was determined to 30 ng/ml in a direct assay set-up and to 10 ng/ml in a sandwich assay format. Exposure of doxorubicin, troglitazone, quinidine and cobalt chloride to the cardiomyocytes for periods of 6 to 24 hours gave significant SPR responses, while substances with low-toxicity showed insignificant effects (ascorbic acid, methotrexate). The SPR results were verified with a validated immunochemiluminescence method which showed a correlation of r 2 = 0.790.

show abstract

National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure

Cited by 94 publications

References 28 publications

B-type natriuretic peptide in the evaluation of cardiac function

B-type natriuretic peptide in the evaluation of cardiac function

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Monitoring of troponin release from cardiomyocytes during exposure to toxic substances using surface plasmon resonance biosensing

Contact Info

Product

Resources

About